Patents Assigned to Oregon Health and Science University
  • Publication number: 20210284599
    Abstract: Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.
    Type: Application
    Filed: August 14, 2017
    Publication date: September 16, 2021
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Thomas S. SCANLAN, James Matthew MEINIG, Skylar J. FERRARA, Tapasree BANERJI, Tania BANERJI
  • Publication number: 20210275569
    Abstract: Provided herein are methods, compounds, and compositions for safely reducing thrombopoietin in a cell or an individual. Such methods, compounds, and compositions maintain platelet count within a safe hemostatic range. Such methods, compounds, and compositions are useful to safely treat, prevent, or ameliorate a disease that can benefit from platelet count reduction in an individual. Such methods, compounds, and compositions are useful for treating or preventing diseases in which thrombopoietin contributes to the presence or activation of platelets contributes to and promotes disease initiation or progression, and/or adversely affects disease outcome.
    Type: Application
    Filed: July 16, 2019
    Publication date: September 9, 2021
    Applicants: Aronora, Inc., Oregon Health & Science University, Ionis Pharmaceuticals, Inc.
    Inventors: Andras Gruber, Erik Tucker, Brett P. Monia, Alexey Revenko
  • Patent number: 11104654
    Abstract: Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: August 31, 2021
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Thomas S. Scanlan, Andrew Placzek, Tapasree Banerji, Sky Ferrara, James Matthew Meinig
  • Patent number: 11091779
    Abstract: Methods of inducing a CD8+ T cell response to a heterologons antigen in which at least 10% of the CD8+ T cells are MHC-E restricted are disclosed. The method involves immunizing with a CMV vector that does not express UL128 and UL130 proteins. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, a UL40 protein, and a US28 protein but that do not express an active UL128 and UL130 protein. Also, disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active UL40 protein, UL128 protein, UL130 protein, and optionally a US28 protein. Also disclosed are recombinant CMV vectors comprising nucleic acids encoding a heterologous protein antigen, but that do not express an active US28 protein, UL128 protein, UL130 protein, and optionally a UL40 protein.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: August 17, 2021
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Klaus Frueh, Louis Picker, Scott Hansen, Jonah Sacha, Daniel Malouli
  • Patent number: 11091775
    Abstract: The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising Mycobacterium tuberculosis (Mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: August 17, 2021
    Assignees: Oregon Health and Science University, International AIDS Vaccine Initative, Inc.
    Inventors: Thomas G. Evans, Ravi P. Anantha, Aurelio M. Bonavia, Dominick J. Laddy, Louis Picker, Scott Hansen, Guangwu Xu
  • Publication number: 20210246512
    Abstract: Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
    Type: Application
    Filed: February 11, 2021
    Publication date: August 12, 2021
    Applicants: Celator Pharmaceuticals, Inc., Oregon Health & Science University
    Inventors: Max GORDON, Paul TARDI, Jeffrey TYNER, Lawrence MAYER
  • Publication number: 20210236657
    Abstract: Nerve-specific fluorophore formulations for direct or systemic administration are described. The formulations can be used in fluorescence-guided surgery (FGS) to aid in nerve preservation during surgical interventions.
    Type: Application
    Filed: August 6, 2019
    Publication date: August 5, 2021
    Applicants: OREGON HEALTH & SCIENCE UNIVERSITY, OREGON STATE UNIVERSITY
    Inventors: Summer L. Gibbs, Connor W. Barth, Wathah G. Alani, Vidhiben Shah, Lei Wang
  • Publication number: 20210236500
    Abstract: Provided are methods and pharmaceutical combinations utilizing a phospholipase A2 inhibitor for the inhibition of treatment-induced autophagy.
    Type: Application
    Filed: April 14, 2021
    Publication date: August 5, 2021
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: George Thomas, Jennifer Podolak, Hui-wen Lue, Kevin Kolahi
  • Publication number: 20210235374
    Abstract: A user equipment (UE) registers on a first Public Land Mobile Network (PLMN) and, while in an idle mode, receives a Multimedia Broadcast Multicast Services (MBMS) service. The UE determines whether to perform a periodic network reselection search for a higher priority PLMN while in the idle mode, wherein the UE determines whether to perform the periodic network reselection search based on reception of the MBMS service. The UE may postpone the periodic network reselection search for a period of time while the UE receives the MBMS service in the idle mode. The UE may postpone the periodic network reselection search for a period of time while the UE receives the MBMS service in the idle mode. The UE may interleave the periodic network reselection search with the reception of transmission bursts of the MBMS service, the search being performed on frequencies other than that of the MBMS transmission.
    Type: Application
    Filed: July 26, 2019
    Publication date: July 29, 2021
    Applicant: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Jeffrey W Tyner, Cristina Tognon, Brian J Druker, Daniel Bottomly, Beth Wilmot, Stephen Kurtz, Samantha Savage, Nicola Long, Anna Reister Shultz, Elie Traer, Shannon K McWeeney
  • Publication number: 20210223269
    Abstract: The present disclosure provides biomarkers for the detection of coronary artery disease. The biomarkers comprise oxylipins and the detection, identification, and quantification can provide a means to diagnose, prognose, and manage subject at risk for cardiovascular disease. Methods of also provided for the detection and quantification of the oxylipins, for treating, and for predicting the survival of a subject at high risk for coronary artery disease.
    Type: Application
    Filed: January 22, 2021
    Publication date: July 22, 2021
    Applicants: Oregon State University, Oregon Health & Science University
    Inventors: Manuel Garcia-Jaramillo Rodriguez, Gerd Bobe, Claudia Susanne Maier, Donald Bradley Jump, Armando Alcázar-Magaña, Dai-Trang Elizabeth Le, Sanjiv Kaul, Nabil J. Alkayed
  • Patent number: 11051814
    Abstract: Surgical clips and surgical applicators used in performing rapid tissue closure in either minimally invasive surgeries or traditional open procedures are provided. In one example approach, a surgical clip comprises opposing sides extending from a top portion and terminating at tips positioned below the top portion. The resting position of the clip is its closed position, and in the closed position, the tips are set at a first distance apart. Each side has a cut-out (or hole or aperture) opposite one another. Each cut-out is fully surrounded by the side and does not extend to the top or tips. Each cut-out is configured to engage an inwardly turned hook at the end of a clip array or clip applicator such that the sides bend outwardly away from each other when pressure is applied on the top portion of the clip, thereby placing the clip in an open position.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: July 6, 2021
    Assignee: Oregon Health & Science University
    Inventors: Neil Roundy, Rachel Dreilinger
  • Patent number: 11055565
    Abstract: Disclosed herein are methods and systems for the identification and characterization of perivascular spaces in the cerebral vasculature using magnetic resonance imaging (MRI) data. The disclosed methods allow for automated and unbiased quantification of enlarged perivascular space (ePVS) in a subject, and thus can provide a substantial improvement over manual grading methods used in the art. An example method includes receiving an MRI dataset including voxels having intensity values, identifying a set of candidate voxels within the MRI dataset based on the intensity values; grouping the set of candidate voxels into a set of first clusters; filtering the set of first clusters to generate a set of second clusters; and filtering the set of second clusters based on a morphologic constraint, thereby identifying an enlarged perivascular space in the MRI dataset.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: July 6, 2021
    Assignee: Oregon Health & Science University
    Inventors: Erin L. Boespflug, David Lahna, Daniel Schwartz, Lisa C Silbert
  • Patent number: 11049247
    Abstract: Methods, systems, and apparatuses for detecting and describing heterogeneity in a cell sample are disclosed herein. A plurality of fields of view (FOV) are generated for one or more areas of interest (AOI) within an image of the cell sample are generated. Hyperspectral or multispectral data from each FOV is organized into an image stack containing one or more z-layers, with each z-layer containing intensity data for a single marker at each pixel in the FOV. A cluster analysis is applied to the image stacks, wherein the clustering algorithm groups pixels having a similar ratio of detectable marker intensity across layers of the z-axis, thereby generating a plurality of clusters having similar expression patterns.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: June 29, 2021
    Assignees: Ventana Medical Systems, Inc., OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Michael Barnes, David Chafin, Karl Garsha, Thomas M. Grogan, Esteban Roberts, Benjamin Stevens, Franklin Ventura, Christophe Chefd'hotel, Kandavel Shanmugam, Joe Gray, Damien Ramunno-Johnson, Tothu Tania Vu, Brian J. Druker, Thomas Jacob
  • Patent number: 11028444
    Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: June 8, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Arizona Board of Regents on behalf of the University of Arizona, Queen Mary University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat de Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Würzburg
    Inventors: Lisa M. Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaløy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George W. Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
  • Patent number: 11028397
    Abstract: Disclosed herein are synthetic oligoribonucleotides that form hairpin loop structures. The oligoribonucleotides can be used in the treatment of viral infection including prophylactic treatments. The oligoribonucleotides can also be used as adjuvants.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: June 8, 2021
    Assignee: Oregon Health & Science University
    Inventor: John Hiscott
  • Publication number: 20210153738
    Abstract: Methods and systems for identifying CNV membranes and vasculature in images obtained using noninvasive imaging techniques are described. An example method includes generating, by a first model based on at least one image of a retina of a subject, a membrane mask indicating a location of a CNV membrane in the retina. The method further includes generating, by a second model based on the membrane mask and the at least one image, a vasculature mask of the retina of the subject, the vasculature mask indicating CNV vascularization in the retina.
    Type: Application
    Filed: November 19, 2020
    Publication date: May 27, 2021
    Applicant: Oregon Health & Science University
    Inventors: Yali Jia, Jie Wang
  • Publication number: 20210145277
    Abstract: Disclosed herein are methods and systems for optical coherence tomography (OCT) angiography (OCTA). An interleaved scanning pattern is described herein for both raster and bidirectional scanning methods. The interleaved scanning pattern provides B-scans with different scanning intervals. OCTA images based on the B-scans may be combined to obtain a high dynamic range (HDR) OCTA image. Other embodiments may be described and claimed.
    Type: Application
    Filed: November 13, 2020
    Publication date: May 20, 2021
    Applicant: Oregon Health & Science University
    Inventors: Xiang Wei, Yali Jia
  • Patent number: 11009394
    Abstract: Devices, systems, reagents, and methods for the performance of multi-spectrum super resolution microscopy are disclosed.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: May 18, 2021
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Joe Gray, Summer Dowell, Xiaolin Nan, Steven Jacques, Don Kania
  • Publication number: 20210130849
    Abstract: Methods are disclosed for correcting a mutant allele of a gene of interest in a primate cell. The methods include a) introducing a non-naturally occurring targeted nuclease and site-specific nucleotide-binding guide that act together to introduce double-stranded breaks in the mutant allele into the primate cell, wherein: i) the primate cell is undergoing mitotic cell division; ii) the primate cell comprises a genome that is heterozygous for the mutant allele, such that the genome comprises one copy of the mutant allele and one copy of a wild-type allele; iii) single-stranded oligonucleotides homologous to the wild-type allele are not introduced into the primate cell. The methods also include b) allowing the primate cell to activate homology-directed repair of the double-stranded DNA breaks in the mutant allele, thereby correcting the mutant allele using the normal wild-type allele as a repair template and producing a primate cell that is homozygous for the wild-type allele.
    Type: Application
    Filed: April 20, 2018
    Publication date: May 6, 2021
    Applicant: Oregon Health & Science University
    Inventors: Shoukhrat Mitalipov, Nuria Marti-Gutierrez
  • Patent number: 10995121
    Abstract: Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: May 4, 2021
    Assignee: Oregon Health & Science University
    Inventors: Klaus Frueh, Scott G. Hansen, Jay Nelson, Louis Picker, Patrizia Caposio